If you are one of these estimated 2 million breast cancer survivors in the U.S., your ob-gyn now has new guidance. The American College of Obstetricians and Gynecologists has issued a practice bulletin with new information on how to manage these health issues.
"More and more women are living with breast cancer, and all these [cancer] drugs have gynecologic side effects," says Mindy Goldman, MD, a clinical professor of obstetrics and gynecology and director of the Women's Cancer Care Program at the University of California San Francisco. She developed the report with the ACOG's Committee on Practice Bulletins, Gynecology.
The guidelines are published in Obstetrics & Gynecology.
As more ob-gyns read the new guidelines, "I think women should feel more comfortable in asking questions of their ob-gyns and hopefully get answers," Goldman says.
The guidelines offer options to deal with the issues, based on scientific evidence.
Birth control options, for instance, can include barrier methods such as condoms and diaphragms, the copper IUD, and sterilization, the guidelines say.
The use of the cancer drug tamoxifen is addressed. "It's well-known that tamoxifen can increase uterine cancer risk in postmenopausal women," Goldman tells WebMD. "It turns out it's pretty rare and almost always [occurs] with abnormal bleeding."
For that reason, the guidelines suggest that a routine biopsy and ultrasound are not needed if women past menopause take the drug but do not have bleeding.
Pregnancy after breast cancer is not thought to raise the risk of recurrence.
Younger breast cancer patients who want to have children should be referred to a fertility specialist. It may be possible to freeze eggs before treatment starts.
Antidepressants can help relieve hot flashes that can occur with cancer drugs.
Drugs to preserve bone should be considered if bone density becomes low.
Vaginal lubricants without hormones can help vaginal dryness, which is linked with sexual dissatisfaction.
Goldman has served as a consultant on hormone therapy and breast cancer risk for Wyeth, which is now part of Pfizer and makes a hormone replacement drug.